| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Net loss | NaN | -13,449 |
| Depreciation | NaN | 6 |
| Stock based compensation | NaN | 624 |
| Change in deferred tax liability, net | NaN | 358 |
| Intangible asset and goodwill impairment expenses | NaN | 9,684 |
| Reduction in the carrying amount of operating lease right of use asset | NaN | 7 |
| Finance expense (income) | NaN | -3 |
| Net loss | -725 | NaN |
| Operating lease liability | NaN | -7 |
| Depreciation | 2 | NaN |
| Other current assets | NaN | 137 |
| Finance income | -14 | NaN |
| Other account payables | NaN | 359 |
| Other current assets | -34 | NaN |
| Accounts payable | NaN | 21 |
| Other account payables | 66 | NaN |
| Net cash used in operating activities | NaN | -2,531 |
| Accounts payable | 68 | NaN |
| Deposit for operating right of use assets | NaN | 18 |
| Net cash used in operating activities | -541 | NaN |
| Withdrawal from (investment in) short term deposit | NaN | -975 |
| Withdrawal from short term deposit | 200 | NaN |
| Investment in restricted deposit | NaN | 9 |
| Deposit for operating right of use assets | 18 | NaN |
| Purchase of property, plant and equipment | -1 | 7 |
| Net cash provided by investing activities | -217 | 941 |
| Increase (decrease) in cash and cash equivalents | -758 | -1,590 |
| Cash and cash equivalents at the beginning of period | 1,678 | 3,268 |
| Cash and cash equivalents at the end of period | 920 | 1,678 |
Revium Rx. (RVRC)
Revium Rx. (RVRC)